An­tipsy­chot­ic from Lund­beck, Ot­su­ka flops again in PhI­II tri­als — this time in bipo­lar pa­tients

New Lund­beck CEO Deb­o­rah Dun­sire has more bad news to con­tend with, five months in­to her ap­point­ment. The Dan­ish drug­mak­er — which is bat­tling with gener­ics eat­ing in­to sales of three key drugs and a re­cent set­back for schiz­o­phre­nia — on Thurs­day said a pair of piv­otal tri­als failed to show its block­buster an­tipsy­chot­ic drug, br­ex­pipra­zole, helped pa­tients with bipo­lar dis­or­der.

The drug, dis­cov­ered by Ot­su­ka and part­nered with the Japan­ese com­pa­ny, is al­ready ap­proved for use in ma­jor de­pres­sion and schiz­o­phre­nia and is sold un­der the brand name Rex­ul­ti.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER